308 related articles for article (PubMed ID: 19477910)
1. RAGE: therapeutic target and biomarker of the inflammatory response--the evidence mounts.
Ramasamy R; Yan SF; Schmidt AM
J Leukoc Biol; 2009 Sep; 86(3):505-12. PubMed ID: 19477910
[TBL] [Abstract][Full Text] [Related]
2. The RAGE axis and endothelial dysfunction: maladaptive roles in the diabetic vasculature and beyond.
Ramasamy R; Yan SF; Schmidt AM
Trends Cardiovasc Med; 2005 Oct; 15(7):237-43. PubMed ID: 16226677
[TBL] [Abstract][Full Text] [Related]
3. Decreased levels of soluble receptor for advanced glycation end products in patients with rheumatoid arthritis indicating deficient inflammatory control.
Pullerits R; Bokarewa M; Dahlberg L; Tarkowski A
Arthritis Res Ther; 2005; 7(4):R817-24. PubMed ID: 15987483
[TBL] [Abstract][Full Text] [Related]
4. Receptor for advanced glycation end products (RAGE) in a dash to the rescue: inflammatory signals gone awry in the primal response to stress.
Herold K; Moser B; Chen Y; Zeng S; Yan SF; Ramasamy R; Emond J; Clynes R; Schmidt AM
J Leukoc Biol; 2007 Aug; 82(2):204-12. PubMed ID: 17513693
[TBL] [Abstract][Full Text] [Related]
5. RAGE in inflammation: a new therapeutic target?
Bierhaus A; Stern DM; Nawroth PP
Curr Opin Investig Drugs; 2006 Nov; 7(11):985-91. PubMed ID: 17117586
[TBL] [Abstract][Full Text] [Related]
6. Soluble receptor for advanced glycation end products: a new biomarker in diagnosis and prognosis of chronic inflammatory diseases.
Maillard-Lefebvre H; Boulanger E; Daroux M; Gaxatte C; Hudson BI; Lambert M
Rheumatology (Oxford); 2009 Oct; 48(10):1190-6. PubMed ID: 19589888
[TBL] [Abstract][Full Text] [Related]
7. Endogenous secretory receptor for advanced glycation end-products and cardiovascular disease in end-stage renal disease.
Nishizawa Y; Koyama H
J Ren Nutr; 2008 Jan; 18(1):76-82. PubMed ID: 18089449
[TBL] [Abstract][Full Text] [Related]
8. V domain of RAGE interacts with AGEs on prostate carcinoma cells.
Allmen EU; Koch M; Fritz G; Legler DF
Prostate; 2008 May; 68(7):748-58. PubMed ID: 18302220
[TBL] [Abstract][Full Text] [Related]
9. Receptor for advanced glycation end products--soluble form and gene polymorphisms in chronic haemodialysis patients.
Kalousová M; Jáchymová M; Mestek O; Hodková M; Kazderová M; Tesar V; Zima T
Nephrol Dial Transplant; 2007 Jul; 22(7):2020-6. PubMed ID: 17347281
[TBL] [Abstract][Full Text] [Related]
10. The AGE/RAGE axis in diabetes-accelerated atherosclerosis.
Jandeleit-Dahm K; Watson A; Soro-Paavonen A
Clin Exp Pharmacol Physiol; 2008 Mar; 35(3):329-34. PubMed ID: 18290873
[TBL] [Abstract][Full Text] [Related]
11. Receptor for Advanced Glycation Endproducts (RAGE): a formidable force in the pathogenesis of the cardiovascular complications of diabetes & aging.
Yan SF; D'Agati V; Schmidt AM; Ramasamy R
Curr Mol Med; 2007 Dec; 7(8):699-710. PubMed ID: 18331228
[TBL] [Abstract][Full Text] [Related]
12. RAGE, vascular tone and vascular disease.
Farmer DG; Kennedy S
Pharmacol Ther; 2009 Nov; 124(2):185-94. PubMed ID: 19616578
[TBL] [Abstract][Full Text] [Related]
13. Mechanisms of disease: advanced glycation end-products and their receptor in inflammation and diabetes complications.
Yan SF; Ramasamy R; Schmidt AM
Nat Clin Pract Endocrinol Metab; 2008 May; 4(5):285-93. PubMed ID: 18332897
[TBL] [Abstract][Full Text] [Related]
14. Identification of mouse orthologue of endogenous secretory receptor for advanced glycation end-products: structure, function and expression.
Harashima A; Yamamoto Y; Cheng C; Tsuneyama K; Myint KM; Takeuchi A; Yoshimura K; Li H; Watanabe T; Takasawa S; Okamoto H; Yonekura H; Yamamoto H
Biochem J; 2006 May; 396(1):109-15. PubMed ID: 16503878
[TBL] [Abstract][Full Text] [Related]
15. Expression and purification of the soluble isoform of human receptor for advanced glycation end products (sRAGE) from Pichia pastoris.
Ostendorp T; Weibel M; Leclerc E; Kleinert P; Kroneck PM; Heizmann CW; Fritz G
Biochem Biophys Res Commun; 2006 Aug; 347(1):4-11. PubMed ID: 16806067
[TBL] [Abstract][Full Text] [Related]
16. Glycation, inflammation, and RAGE: a scaffold for the macrovascular complications of diabetes and beyond.
Yan SF; Ramasamy R; Naka Y; Schmidt AM
Circ Res; 2003 Dec; 93(12):1159-69. PubMed ID: 14670831
[TBL] [Abstract][Full Text] [Related]
17. The role of RAGE in the pathogenesis of intestinal barrier dysfunction after hemorrhagic shock.
Raman KG; Sappington PL; Yang R; Levy RM; Prince JM; Liu S; Watkins SK; Schmidt AM; Billiar TR; Fink MP
Am J Physiol Gastrointest Liver Physiol; 2006 Oct; 291(4):G556-65. PubMed ID: 16751175
[TBL] [Abstract][Full Text] [Related]
18. RAGE: a journey from the complications of diabetes to disorders of the nervous system - striking a fine balance between injury and repair.
Rong LL; Gooch C; Szabolcs M; Herold KC; Lalla E; Hays AP; Yan SF; Yan SS; Schmidt AM
Restor Neurol Neurosci; 2005; 23(5-6):355-65. PubMed ID: 16477098
[TBL] [Abstract][Full Text] [Related]
19. Serum levels of soluble form of receptor for advanced glycation end products (sRAGE) are positively associated with circulating AGEs and soluble form of VCAM-1 in patients with type 2 diabetes.
Nakamura K; Yamagishi S; Adachi H; Matsui T; Kurita-Nakamura Y; Takeuchi M; Inoue H; Imaizumi T
Microvasc Res; 2008 May; 76(1):52-6. PubMed ID: 18474381
[TBL] [Abstract][Full Text] [Related]
20. RAGE axis: Animal models and novel insights into the vascular complications of diabetes.
Naka Y; Bucciarelli LG; Wendt T; Lee LK; Rong LL; Ramasamy R; Yan SF; Schmidt AM
Arterioscler Thromb Vasc Biol; 2004 Aug; 24(8):1342-9. PubMed ID: 15155381
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
